Active substanceLatanoprost + TimololLatanoprost + Timolol
Similar drugsTo uncover
  • Duoprost
    drops d / eye 
  • Xalacom®
    drops d / eye 
  • Dosage form: & nbspeye drops
    Composition:

    In 1 ml of the drug contains

    Active substances: latanoprost-0.05 mg, timolol maleate in terms of timolol - 5.0 mg;

    Excipients: Disodium phosphate dodecahydrate 11.85 mg, sodium dihydrogen phosphate dihydrate 5.2 mg, sodium chloride 4.1 mg, benzalkonium chloride 0.2 mg, 1M sodium hydroxide solution / 1M hydrochloric acid solution to pH 6.0 ± 0.1, purified water - up to 1 ml.

    Description:A clear, colorless solution.
    Pharmacotherapeutic group:Anti-glaucoma combined (prostaglandin F2-alpha analogue synthetic + beta adrenoblocker)
    ATX: & nbsp

    S.01.E.D.   Beta-blockers

    S.01.E.D.51   Timolol in combination with other drugs

    Pharmacodynamics:

    Duoprost is a combined preparation.

    Latanoprost is an analog of prostaglandin F2α and a selective agonist FP receptors. Reduces intraocular pressure by increasing the outflow of aqueous humor and has anti-glaucoma effect. The main mechanism of action of latanoprost is associated with an increase in uveoscleral outflow. Does not have a significant effect on the production of aqueous humor and does not affect the hemato-ophthalmic barrier.

    Timolol - a non-selective beta-adrenoreceptor blocker with a slight internal sympathomimetic and membrane-stabilizing activity (SMA). With topical application lowers the intraocular pressure by reducing the formation of watery moisture and a small increase in its outflow.

    Pharmacokinetics:

    Latanoprost

    The maximum concentration in aqueous humor (about 15-30 ng / ml) is achieved 2 hours after instillation into the eye. After applying eye drops latanoprost is distributed, first of all, in the anterior segment of the eye, in the conjunctiva and in the eyelids. Only a small amount of the drug reaches the posterior segment. Latanoprost is subjected to hydrolysis in the cornea under the action of esterases to form a biologically active acid. Metabolism of latanoprost acid in the tissues of the eye practically does not occur. The main metabolism occurs in the liver. The half-life of the plasma is 17 min. The main metabolites, 1,2-dinor- and 1,2,3,4-tetranor metabolites, do not have or have weak biological activity and, mainly, are excreted in urine.

    Timolol

    With topical application timolol quickly penetrates through the cornea.After instillation of eye drops, the maximum concentration of timolol in the aqueous humor of the eye is reached after 1 hour. The half-life period from the plasma is 6 hours. It enters the systemic bloodstream in an insignificant amount by the absorption through the vessels of the conjunctiva, the nasal mucosa and the lacrimal tract. The excretion of timolol metabolites is mainly carried out by the kidneys.

    Indications:Open angle glaucoma, increased intraocular pressure.
    Contraindications:

    - Bronchial asthma, or a history of bronchial asthma, chronic obstructive pulmonary disease;

    - sinus bradycardia, atrioventricular blockade of the second - third degree, decompensated chronic heart failure II-III degree, cardiogenic shock;

    - increased sensitivity to any component of this drug;

    - age to 18 years;

    - the period of lactation.

    Carefully:Inflammatory, neovascular, zakratougolnaya or congenital glaucoma, open-angle glaucoma in combination with pseudophakia, pigmentary glaucoma (due to lack of sufficient experience of the drug); aphakia, pseudo-aphakia with a rupture of the posterior capsule of the lens,patients with risk factors for macular edema (in the treatment with latanoprost, cases of development of macular edema, including cystoid edema) are described.
    Pregnancy and lactation:

    Adequate and strictly controlled clinical studies on the safety of the drug during pregnancy and lactation (breastfeeding) was not conducted.

    The use of the drug during pregnancy is possible only if the intended benefit to the mother exceeds the potential risk to the fetus or child.

    The drug should not be given to breastfeeding women, or breastfeeding should be discarded (timolol, latanoprost and its metabolites can penetrate into the mother's milk).

    Dosing and Administration:

    Locally.

    Bury one drop in the eye (a) once a day. If one dose was missed, then in the future it is necessary to continue treatment, introducing the next dose as usual.

    If a patient is assigned more than one preparation for topical administration for an ophthalmic disease, then these drugs should be administered at intervals of not less than five minutes.

    Side effects:

    From the side of the organ of vision: blurred vision, blepharitis, cataracts, conjunctivitis, allergic lesions of the conjunctiva (including follicles, conjunctival papillary reactions, pinpoint hemorrhages, etc.), cornea lesions (erosion, pigmentation, spot keratitis, etc.), refractive disorders, hyperemia of the eye , eye irritation, eye pain, increased pigmentation of the iris, keratitis, photophobia, loss of fields of vision.

    Infections: sinusitis, upper respiratory tract infections and other infections.

    Metabolic and nutritional disorders: diabetes mellitus, hypercholesterolemia.

    Mental disorders: depression.

    From the nervous system: headache.

    Vascular disorders: increase in blood pressure.

    From the skin and subcutaneous tissues: hypertrichosis, rash and skin changes (irritation, chalazion, etc.).

    From the side of the musculoskeletal system and connective tissue: arthritis.

    The following are other undesirable effects that may occur with therapy with certain Duoprost components (apart from the above).

    Latanoprost:

    From the side of the organ of vision: irritation of the eyes (burning sensation, sensation of sand in the eyes, itching,tingling and sensation of foreign body); transient point erosions of the epithelium, edema of the eyelids, edema and erosion of the cornea; lengthening, thickening, increasing the number and increasing pigmentation of eyelashes and gun hair; iritis / uveitis; macular edema, incl. cystoid; changing the direction of growth of eyelashes, sometimes causing eye irritation; blurred vision.

    From the skin and subcutaneous tissues: skin rash, darkening of the skin of the eyelids and local skin reactions on the eyelids.

    From the nervous system: dizziness.

    On the part of the respiratory system: bronchospasm (including acute attacks or exacerbation of the disease in patients with bronchial asthma in the anamnesis), dyspnea.

    From the side of the musculoskeletal system and connective tissue: pain in the muscles / joints.

    General and local reactions: nonspecific pain in the chest.

    Timolol (in the form of eye drops):

    From the immune system: systemic allergic reactions, incl. anaphylaxis, angioedema, urticaria, localized and generalized rash.

    Metabolic and nutritional disorders: anorexia, latent symptoms of hypoglycemia in patients with diabetes mellitus.

    Mental disorders: behavioral changes and mental disorders, incl. confusion, hallucinations, anxiety, disorientation, nervousness, memory loss, decreased libido, insomnia and nightmares.

    From the nervous system: cerebral ischemia, acute disorders of cerebral circulation, dizziness, increased symptoms of myasthenia gravis gravis, paresthesia, drowsiness, fainting.

    From the side of the organ of vision: cystoid macular edema, decreased sensitivity of the cornea; abruption of the choroid after filtration surgical interventions; ptosis, visual impairment, incl. change refraction and diplopia.

    From the side of the hearing and vestibular organs: noise in ears.

    From the heart: arrhythmia, bradycardia, cardiac arrest, heart failure, blockade of intracardiac conduction, palpitation, progression of angina pectoris.

    Vascular disorders: intermittent claudication, coldness of the hands and feet, lowering blood pressure, Raynaud's syndrome.

    On the part of the respiratory system: bronchospasm (mainly in patients with previous bronchospastic diseases), cough, shortness of breath, nasal congestion, pulmonary edema and respiratory failure.

    From the gastrointestinal tract: diarrhea, dry mouth, dyspepsia, nausea, retroperitoneal fibrosis.

    From the skin and subcutaneous tissues: alopecia, pseudo-pemphigoid, psoriasis-like rash or exacerbation of psoriasis.

    From the side of the musculoskeletal system and connective tissue: systemic lupus erythematosus.

    On the part of the reproductive system and mammary glands: impotence, Peyronie's disease.

    General and local: asthenia / fatigue, chest pain, swelling.
    Overdose:

    Symptoms: caused by latanoprost - eye irritation, conjunctival or episcleral hyperemia, dizziness; caused by timolol - headache, arrhythmia, bradycardia, bronchospasm, nausea, vomiting.

    Treatment: immediately wash eyes with water or 0.9% solution of sodium chloride, symptomatic therapy.

    Interaction:

    When used simultaneously with blockers of "slow" calcium channels, drugs that reduce the activity of catecholamines, beta-blockers, antiarrhythmics (including amiodarone and quinidine), cardiac glycosides, cholinomimetics, narcotic analgesics and monoamine oxidase inhibitors, hypotensive action and / ordevelopment of severe bradycardia. With the simultaneous use of timolol with epinephrine, mydriasis sometimes developed.

    Special instructions:

    The drug can cause a gradual change in eye color by increasing the amount of brown pigment in the iris, periodic monitoring of the treating physician is recommended. The drug contains a preservative benzalkonium chloride, which can be absorbed by contact lenses and have a damaging effect on the eye tissue. Therefore, it is necessary to remove contact lenses and re-install them 15 minutes after instillation.

    Effect on the ability to drive transp. cf. and fur:Burying eye drops can cause a transient sensation of "shroud before your eyes" for several minutes, which should be taken into account when driving a car and working with moving mechanisms. While this effect does not disappear, patients should not drive a car or use sophisticated technology.
    Form release / dosage:

    Eye drops.

    Packaging:

    For 2.5 ml of solution in a polymer bottle-dropper with a capacity of 5 ml closed with a polymer lid with a safety ring. One bottle-dropper along with instructions for use in a cardboard pack.

    Storage conditions:

    In the dark place at a temperature of 2 ° to 8 ° C. After opening the vial, the drug should be stored at a temperature of no higher than 25 ° C and used within 4 weeks.

    Inaccessible to children!

    Shelf life:

    3 years.

    Do not use after the expiration date stated on the package!
    Terms of leave from pharmacies:On prescription
    Registration number:LP-002006
    Date of registration:19.02.2013
    The owner of the registration certificate:K.O. Ромфарм Компани С.Р.Л.K.O. Ромфарм Компани С.Р.Л. Romania
    Manufacturer: & nbsp
    Representation: & nbspРомфарма ОООРомфарма ООО
    Information update date: & nbsp17.11.2015
    Illustrated instructions
      Instructions
      Up